Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by lv_426on Mar 23, 2020 2:09pm
66 Views
Post# 30838514

RE:RE:NR Today

RE:RE:NR Today
Ingiboy wrote: What is this NR today:

"RepliCel Life Sciences Inc. has provided commentary today on the recent publication of a paper in the prestigious Journal of the American Academy of Dermatology, entitled: "Autologous Cell-based Therapy for Male and Female Pattern Hair Loss using Dermal Sheath Cup Cells: A Randomized Placebo-Controlled Double-Blinded Dose Finding Clinical Study."

This is Replicel's long overdue response to this publication of the Shiseido RCH-01 Trial.  It makes the case that RCH-01 does indeed show promise.  It also makes a very detailed case that Replicel has done it's part to support the contract it made with Shiseido.

Unfortunately what is missing is when Shiseido will do the next phase of research.  Also missing is some clarity of what is the status of the relationship between the two companies.








Who shiseido will do more research? Maybe they looked at the results and figured not worth it. Wheres the time frame from replicel's long over due trial? Yes, I know they are waiting on the injector but no mention. I think the beer flu has killed replicel. The world financial situation is too much.
Bullboard Posts